-
Something wrong with this record ?
CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours
Reiniš, M, Šímová, J, Indrová, M, Bieblová, J, Bubeník, J.
Language English Country Greece
NLK
Free Medical Journals
from 2006 to 1 year ago
- MeSH
- CpG Islands MeSH
- Financing, Organized MeSH
- Genes, MHC Class I MeSH
- Humans MeSH
- Human papillomavirus 16 metabolism MeSH
- Disease Models, Animal MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Neoplasms genetics therapy virology MeSH
- Oligonucleotides chemistry therapeutic use MeSH
- Recurrence MeSH
- Neoplasm, Residual drug therapy MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC class I-positive and -deficient tumours after debulking the tumour mass by chemotherapy or surgery. We employed an animal model resembling human papillomavirus (HPV) 16-associated tumours. Tumour cell lines with distinct cell surface expression of the MHC class I molecules were injected into syngeneic C57BL/6 mice, and the growing tumours were either subjected to cytoreductive chemotherapy with ifosfamide derivative, CBM-4A, or surgically removed. Subsequent treatment with synthetic CpG ODN significantly blocked the growth of the recurrent tumours. Our results indicate that the therapy with CpG ODN can be effective for the treatment of minimal residual tumour disease of the tumours that have escaped from the immune surveillance by downmodulating the MHC class I expression.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10003263
- 003
- CZ-PrNML
- 005
- 20120709213945.0
- 008
- 100209s2007 gr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Reiniš, Milan $7 xx0083033
- 245 10
- $a CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours / $c Reiniš, M, Šímová, J, Indrová, M, Bieblová, J, Bubeník, J.
- 314 __
- $a Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague 6, Czech Republic
- 520 9_
- $a Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC class I-positive and -deficient tumours after debulking the tumour mass by chemotherapy or surgery. We employed an animal model resembling human papillomavirus (HPV) 16-associated tumours. Tumour cell lines with distinct cell surface expression of the MHC class I molecules were injected into syngeneic C57BL/6 mice, and the growing tumours were either subjected to cytoreductive chemotherapy with ifosfamide derivative, CBM-4A, or surgically removed. Subsequent treatment with synthetic CpG ODN significantly blocked the growth of the recurrent tumours. Our results indicate that the therapy with CpG ODN can be effective for the treatment of minimal residual tumour disease of the tumours that have escaped from the immune surveillance by downmodulating the MHC class I expression.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a CpG ostrůvky $7 D018899
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a geny MHC třídy I $7 D005805
- 650 _2
- $a lidský papilomavirus 16 $x metabolismus $7 D052162
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a reziduální nádor $x farmakoterapie $7 D018365
- 650 _2
- $a nádory $x genetika $x terapie $x virologie $7 D009369
- 650 _2
- $a oligonukleotidy $x chemie $x terapeutické užití $7 D009841
- 650 _2
- $a recidiva $7 D012008
- 700 1_
- $a Šímová, Jana $7 xx0119399
- 700 1_
- $a Indrová, Marie $7 xx0069868
- 700 1_
- $a Bieblová, Jana $7 xx0127729
- 700 1_
- $a Bubeník, Jan, $d 1940- $7 jk01020086
- 773 0_
- $w MED00002350 $t International journal of oncology $g Roč. 30, č. 5 (2007), s. 1247-1251 $x 1019-6439
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20100114162108 $b ABA008
- 991 __
- $a 20120709213920 $b ABA008
- 999 __
- $a ok $b bmc $g 709192 $s 572005
- BAS __
- $a 3
- BMC __
- $a 2007 $b 30 $c 5 $d 1247-1251 $i 1019-6439 $m International journal of oncology $x MED00002350
- LZP __
- $a 2010-b1/dkme